Previous close | 1.5400 |
Open | 1.5400 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.5400 - 1.5400 |
52-week range | 1.5400 - 1.5400 |
Volume | |
Avg. volume | 0 |
Market cap | 20.515M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
With the business potentially at an important milestone, we thought we'd take a closer look at CASI Pharmaceuticals...
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.